Widely used:Recently Viewed
Clear All
$224 Mln
0.13
1.02
--
0
1243.13 %
--
--
--
124078579
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Inhibrx Inc (INBX)
| -61.16 | -7.46 | 9.82 | -17.73 | -23.09 | -- | -- |
|
BSE Sensex
| 13.08 | -1.05 | 2.13 | 24.69 | 11.60 | 16.47 | 11.89 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
|
|---|---|---|---|
|
Inhibrx Inc (INBX)
| 54.22 | -43.58 | 32.45 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$223.65 Mln
$1.85 Mln
$0.00 Mln
$226.86 Mln
$2.17 Mln
High
$10.80 - 39.79
14,475,900
NASDAQ: INBX
La Jolla, CA
https://inhibrx.com
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate... targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California. Address: 11025 North Torrey Pines Road, La Jolla, CA, United States, 92037 Read more
The total asset value of Inhibrx Inc (INBX) stood at $ 297 Mln as on 30-Jun-24
The share price of Inhibrx Inc (INBX) is $14.76 (NASDAQ) as of 04-Oct-2024 16:01 EDT. Inhibrx Inc (INBX) has given a return of -23.09% in the last 3 years.
Inhibrx Inc (INBX) has a market capitalisation of $ 224 Mln as on 02-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Inhibrx Inc (INBX) is 1.02 times as on 02-Oct-2024, a 67% discount to its peers’ median range of 3.12 times.
The P/E ratio of Inhibrx Inc (INBX) is 0.13 times as on 02-Oct-2024.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Inhibrx Inc (INBX) and enter the required number of quantities and click on buy to purchase the shares of Inhibrx Inc (INBX).
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California. Address: 11025 North Torrey Pines Road, La Jolla, CA, United States, 92037
The CEO & director of Mr. Mark Paul Lappe. is Inhibrx Inc (INBX), and CFO & Sr. VP is Mr. Mark Paul Lappe.
There is no promoter pledging in Inhibrx Inc (INBX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Inhibrx Inc (INBX) | Ratios |
|---|---|
|
Return on equity(%)
|
1243.13
|
|
Operating margin(%)
|
-19921.37
|
|
Net Margin(%)
|
88176.36
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Inhibrx Inc (INBX) was $0 Mln.
$-0.12
